Our analysis showed that the use of atezolizumab as adjuvant therapy after platinum-based chemotherapy resulted in a higher ICER compared with the WTP threshold $(27,354/QALY) for the PD-L1 TC ≥ 1% stage II-IIIA group, all stage II-IIIA group, or the ITT group, making atezolizumab less likely to be cost-effective in patients after postoperative platinum-based chemotherapy for early NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.